CORD-19:cb16d307afaecebd683e6d74c8b501ed54b0c9a4 / 35973-36329 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T210","span":{"begin":0,"end":356},"obj":"Sentence"},{"id":"T43496","span":{"begin":0,"end":356},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Glycogen synthase kinase 3 (GSK-3), a regulator of glycogen metabolism, has been well known to be involved in a variety of intracellular signaling, and a lot of GSK-3 inhibitors has been used for the treatment of CNS disorders including Alzheimer's disease (AD) [79] , Parkinson's disease [80] , stroke, traumatic brain injury, and bipolar disorders [81] ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T49","span":{"begin":237,"end":256},"obj":"Disease"},{"id":"T50","span":{"begin":258,"end":260},"obj":"Disease"},{"id":"T51","span":{"begin":269,"end":288},"obj":"Disease"},{"id":"T52","span":{"begin":296,"end":302},"obj":"Disease"},{"id":"T54","span":{"begin":314,"end":326},"obj":"Disease"},{"id":"T55","span":{"begin":320,"end":326},"obj":"Disease"},{"id":"T56","span":{"begin":332,"end":349},"obj":"Disease"},{"id":"T24198","span":{"begin":237,"end":256},"obj":"Disease"},{"id":"T12016","span":{"begin":258,"end":260},"obj":"Disease"},{"id":"T36402","span":{"begin":269,"end":288},"obj":"Disease"},{"id":"T93441","span":{"begin":296,"end":302},"obj":"Disease"},{"id":"T30491","span":{"begin":314,"end":326},"obj":"Disease"},{"id":"T33791","span":{"begin":320,"end":326},"obj":"Disease"},{"id":"T57011","span":{"begin":332,"end":349},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005180"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A53","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0043510"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0004985"},{"id":"A19285","pred":"mondo_id","subj":"T24198","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A54429","pred":"mondo_id","subj":"T12016","obj":"http://purl.obolibrary.org/obo/MONDO_0004975"},{"id":"A9170","pred":"mondo_id","subj":"T36402","obj":"http://purl.obolibrary.org/obo/MONDO_0005180"},{"id":"A74781","pred":"mondo_id","subj":"T93441","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A56333","pred":"mondo_id","subj":"T93441","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A66092","pred":"mondo_id","subj":"T30491","obj":"http://purl.obolibrary.org/obo/MONDO_0043510"},{"id":"A93334","pred":"mondo_id","subj":"T33791","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A75682","pred":"mondo_id","subj":"T57011","obj":"http://purl.obolibrary.org/obo/MONDO_0004985"}],"text":"Glycogen synthase kinase 3 (GSK-3), a regulator of glycogen metabolism, has been well known to be involved in a variety of intracellular signaling, and a lot of GSK-3 inhibitors has been used for the treatment of CNS disorders including Alzheimer's disease (AD) [79] , Parkinson's disease [80] , stroke, traumatic brain injury, and bipolar disorders [81] ."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T210","span":{"begin":0,"end":356},"obj":"Sentence"}],"text":"Glycogen synthase kinase 3 (GSK-3), a regulator of glycogen metabolism, has been well known to be involved in a variety of intracellular signaling, and a lot of GSK-3 inhibitors has been used for the treatment of CNS disorders including Alzheimer's disease (AD) [79] , Parkinson's disease [80] , stroke, traumatic brain injury, and bipolar disorders [81] ."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T40","span":{"begin":237,"end":256},"obj":"Phenotype"},{"id":"T41","span":{"begin":258,"end":260},"obj":"Phenotype"},{"id":"T42","span":{"begin":296,"end":302},"obj":"Phenotype"},{"id":"T43","span":{"begin":332,"end":349},"obj":"Phenotype"}],"attributes":[{"id":"A40","pred":"hp_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0002511"},{"id":"A42","pred":"hp_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/HP_0001297"},{"id":"A43","pred":"hp_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/HP_0007302"}],"text":"Glycogen synthase kinase 3 (GSK-3), a regulator of glycogen metabolism, has been well known to be involved in a variety of intracellular signaling, and a lot of GSK-3 inhibitors has been used for the treatment of CNS disorders including Alzheimer's disease (AD) [79] , Parkinson's disease [80] , stroke, traumatic brain injury, and bipolar disorders [81] ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T16","span":{"begin":314,"end":319},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"}],"text":"Glycogen synthase kinase 3 (GSK-3), a regulator of glycogen metabolism, has been well known to be involved in a variety of intracellular signaling, and a lot of GSK-3 inhibitors has been used for the treatment of CNS disorders including Alzheimer's disease (AD) [79] , Parkinson's disease [80] , stroke, traumatic brain injury, and bipolar disorders [81] ."}